两种实验性埃博拉药物，正在刚果拯救生命

两种实验性埃博拉药物，正在刚果拯救生命

Two experimental Ebola drugs under review in the Democratic Republic of Congo already seem to be saving the lives of many affected by the deadly virus, health authorities announced.

卫生当局宣布，正在刚果民主共和国接受审查的两种实验性埃博拉药物似乎已经挽救了许多受这种致命病毒影响的人的生命。

The two drugs — one developed by Regeneron Pharmaceuticals and the other by researchers with the US National Institutes of Health, which helped fund the study — are antibodies that block the virus.

这两种药物——一种是由Regeneron制药公司开发的，另一种是由美国国立卫生研究院的研究人员开发的，这两个研究机构为阻止病毒的抗体的研究提供了资金支持。

Research has determined that there is already an effective, though experimental vaccine against Ebola — and it’s being used in Congo — but no studies have indicated what treatments are most effective to treat those who are already infected.

研究已经确定，虽然已经有一种有效的抗埃博拉病毒的实验疫苗，而且该疫苗正在刚果使用，但是没有研究表明哪种治疗方法对那些已经感染埃博拉病毒的人最有效。

During the outbreak in West Africa several years ago, studies pointed to an antibody mixture known as ZMapp, but its effectiveness has yet to be clearly proven.

几年前在西非爆发期间，研究指出一种称为ZMAPP的抗体混合物，但其有效性尚未得到明确证明。

So in Congo, researchers decided to compare ZMapp to the Regeneron compound, the one developed by the NIH, called mAb114, and an antiviral drug known as remdesivir.

因此，在刚果，研究人员决定将ZMAPP，与由国家卫生研究院开发的一种叫做MAB114的化合物Regeneron，和一种叫做Remdisivr的抗病毒药物进行比较。

A panel determined that the Regeneron compound was clearly the most effective in fighting Ebola, with the NIH antibody a close second, Dr. Anthony Fauci of the NIH told the Associated Press on Monday.

周一，美国国立卫生研究院的安东尼·福奇博士对美联社说，一个小组认为，该化合物显然是最有效的抗埃博拉病毒药物，NIH抗体紧随其后。

The research revealed that far fewer Ebola patients died among those given either the Regeneron drug or the NIH’s — about 30 percent compared to half under the ZMapp treatment.

研究表明，在服用了再生成素或NIH的患者中，死于埃博拉病毒的患者要少大约30%，而在ZMAPP治疗的患者中，这一比例可以达到50%。

Remarkably, when clients sought care before too much virus spread into their bloodstream, the mortality rate was a mere 6 percent with the Regeneron drug and 11 percent with the NIH’s. The mortality rate for those using ZMapp under the same circumstances was 24 percent.

值得注意的是，当病人在病毒大量进入血液之前接受治疗时，使用再生药物的死亡率仅为6%，而NIH的死亡率为11%。在相同情况下，使用ZMapp的患者的死亡率为24%。

The evidence was strong enough to call a halt to the trial — and to prioritize the use of those two drugs in Congo.

有足够的证据要求停止这项试验，并优先考虑在刚果使用这两种药物。